探索Cadaba fruticosa生物活性化合物用于口腔癌的 in silico和 in vitro方法
Silambarasan Tamil Selvan1, A Venkateshkumar2, Manikandan Alagumuthu3
1Environmental Biotechnology and Bioinformatics Lab, Helix Research Center, Department of General Medicine, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, 602105, Tamil Nadu, India.
Scientific reports
|November 6, 2025
概括
这项研究确定了来自Cadaba fruticosa的3,5-dichlorobenzyl propyl ester作为治疗口腔癌的有力植物化合物. 它有利的药理动力学特征和强烈的与口腔癌蛋白质的结合表明它是一个有前途的新治疗剂.
科学领域:
- 植物化学 植物化学
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 口腔癌仍然是一个重大的全球健康挑战,需要新的治疗策略.
- 植物疗法为药物发现提供了一个有前途的途径,天然化合物表现出多样化的生物活动.
- 识别有效的植物化合物需要对其抗癌潜力和作用机制进行严格的评估.
研究的目的:
- 评估Cadaba fruticosa植物化合物对口腔癌的抗癌疗效.
- 识别和描述具有潜在治疗应用的生物活性化合物.
- 阐明有前途的植物化合物的抗癌作用背后的分子机制.
主要方法:
- 气色谱-质谱 (GC-MS) 用于植物化合物识别.
- 瑞士ADME用于药理动力学分析和毒性预测.
- 网络药理学和分子对接,以评估与口腔癌标的相互作用.
- 用于复杂稳定性分析的分子动力学模拟.
- 在KB-1口腔癌细胞系中对亡基因表达的分析.
- 密度函数理论 (DFT) 用于电子属性评估.
主要成果:
- 确定了10种生物活性植物化合物,其中3,5-二二 propyl ester显示出高强度.
- 根据利宾斯基的五项规则,药理动力学分析表明没有毒性.
- 分子对接揭示了3,5-二博 propyl ester 与口腔癌蛋白 SMAD (-7.9 kcal/mol) 的强有力的结合.
- 分子动力学模拟证实了化合物-蛋白质复合物的稳定性.
- 实验室研究显示,亡基因的调节 (BCL-2的下调,BAD,BAX,caspase-3的上调) 的IC50为38.60μg/ml.
- DFT分析强调了该化合物的电子特性和相互作用潜力.
结论:
- 3,5-二博 propyl ester 是一种强大的植物化合物,对口腔癌具有显著的抗癌活性.
- 该化合物表现出有利的药理动力学特性,并与关键的口腔癌标有强烈的相互作用.
- 这些发现支持3,5-Dichlorobenzyl propyl ester作为治疗口腔癌的新型治疗剂的发展.
相关概念视频
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mutagenicity and Carcinogenicity
1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K


